Neuroprotection for diabetic retinopathy

Developments in Ophthalmology

Volumn 44, Issue , 2009, Pages 56-68

  Imai, Hisanori ^a   Singh, Ravi S J ^a   Fort, Patrice E ^a   Gardner, Thomas W ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT;

ANIMAL; ARTICLE; BLOOD RETINA BARRIER; DIABETIC RETINOPATHY; DRUG EFFECT; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA NERVE CELL;

ANIMALS; BLOOD-RETINAL BARRIER; DIABETIC RETINOPATHY; HUMANS; NEUROPROTECTIVE AGENTS; RETINAL NEURONS;

EID: 67651232736     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000223946     Document Type: Article

References (53)

1. Gardner T W, Antonetti DA, Barber AJ, LaNoue KF, Levison SW: Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47(suppl 2):S253- S262.
2. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF: The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552- 563.
3. Klein R, Klein B: Vision disorders in diabetes. National Diabetes Data Group Diabetes in America. NIH Bethesda, NIH Publication No 95-1468. 1995, pp 293-337.
4. Baumgartner WA: Etiology, pathogenesis, and experimental treatment of retinitis pigmentosa. Med Hypotheses 2000;54:814-824.
5. Juen S, Kieselbach GF: Electrophysiological changes in juvenile diabetics without retinopathy. Arch Ophthalmol 1990;108:372-375.
6. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW: Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin. J Clin Invest 199815;102:783- 791.
7. Lopes de Faria JM, Russ H, Costa VP: Retinal nerve fibre layer loss in patients with type 1 diabetes melli-tus without retinopathy. Br J Ophthalmol 2002;86: 725-728.
8. Mitic LL, Anderson JM: Molecular architecture of tight junctions. Annu Rev Physiol 1998;60:121- 142.
9. Turksen K, Troy TC: Barriers built on claudins. J Cell Sci 2004;117:2435-2447.
10. Tsacopoulos M, Poitry-Yamate CL, Poitry S, Perrottet P, Veuthey AL: The nutritive function of glia is regulated by signals released by neurons. Glia 1997;21:84-91.
11. Barnstable CJ: Glutamate and GABA in retinal circuitry. Curr Opin Neurobiol 1993;3:520-525.
12. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven C, Collen D, Andersen PM, Carmeliet P: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-394.
13. Gilbert RE, Vranes D, Berka JL, Kelly DJ, Cox A, Wu LL, Stacker SA, Cooper ME: Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998;78:1017-1027.
14. Kline CL, Schrufer TL, Jefferson LS, Kimball SR: Glucosamine-induced phosphorylation of the alpha-subunit of eukaryotic initiation factor 2 is mediated by the protein kinase R-like endoplasmic-reticulum associated kinase. Int J Biochem Cell Biol 2006;38:1004-1014.
15. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, Reme CE: HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002;8:718-724.
16. Budd GC, Pansky B, Glatzer L: Preproinsulin mRNA in the rat eye. Invest Ophthalmol Vis Sci 1993;34: 463-469.
17. Barber AJ, Nakamura M, Wolpert EB, Reiter CE, Seigel GM, Antonetti DA, Gardner TW: Insulin rescues retinal neurons from apoptosis by a phosphati-dylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. J Biol Chem 2001;276:32814-32821.
18. Reiter CE, Sandirasegarane L, Wolpert EB, Klinger M, Simpson IA, Barber AJ, Antonetti DA, Kester M, Gardner TW: Characterization of insulin signaling in rat retina in vivo and ex vivo. Am J Physiol Endocrinol Metab 2003;285:E763-774.
19. Seigel GM, Chiu L, Paxhia A: Inhibition of neuroretinal cell death by insulin-like growth factor-1 and its analogs. Mol Vis 2000;6:157-163.
20. Tombran-Tink J, Johnson LV: Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci. 1989;30:1700-1707.
21. Cayouette M, Smith SB, Becerra SP, Gravel C: Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol Dis 1999;6:523-532.
22. Cao W, Tombran-Tink J, Elias R, Sezate S, Mrazek D, McGinnis JF: In vivo protection of photoreceptors from light damage by pigment epitheliumderived factor. Invest Ophthalmol Vis Sci 2001;42: 1646-1652.
23. Ogata N, Wang L, Jo N, Tombran-Tink J, Takahashi K, Mrazek D, Matsumura M: Pigment epithelium derived factor as a neuroprotective agent against ischemic retinal injury. Curr Eye Res 2001;22:245- 252.
24. Seki M, Tanaka T, Nawa H, Usui T, Fukuchi T, Ikeda K, Abe H, Takei N: Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004;53: 2412-2419.
25. Mansour-Robaey S, Clarke DB, Wang YC, Bray GM, Aguayo AJ: Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Natl Acad Sci USA 1994;91:1632-1636.
26. Garcia Valenzuela E, Sharma SC: Rescue of retinal ganglion cells from axotomy-induced apoptosis through TRK oncogene transfer. Neuroreport 1998; 9:3165-3170.
27. Armstrong D, Ueda T, Aljada A, Browne R, Fukuda S, Spengler R, Chou R, Hartnett M, Buch P, Dandona P, Sasisekharan R, Dorey CK: Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis 1998;2:93-104.
28. Barber AJ, Antonetti DA, Gardner TW: Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest Ophthalmol Vis Sci 2000;41:3561-3568.
29. Tang J, Zhu X W, Lust WD, Kern TS: Retina accumulates more glucose than does the embryologi-cally similar cerebral cortex in diabetic rats. Diabetologia 2000;43:1417-1423.
30. Badr GA, Tang J, Ismail-Beigi F, Kern TS: Diabetes downregulates GLUT1 expression in the retina and its microvessels but not in the cerebral cortex or its microvessels. Diabetes 2000;49:1016-1021.
31. Kumagai AK, Vinores SA, Pardridge WM. Pathological upregulation of inner blood-retinal barrier Glut1 glucose transporter expression in diabetes mellitus. Brain Res 1996;706:313-317.
32. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D, Strother JM: Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998;47:815-820.
33. Santiago AR, Hughes JM, Kamphuis W, Schlingemann RO, Ambrosio AF: Diabetes changes ionotropic glutamate receptor subunit expression level in the human retina. Brain Res 2008;1198:153-159.
34. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner T W, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA: Diabetic retinopa-thy: seeing beyond glucose-induced microvascular disease. Diabetes 2006;55:2401-2411.
35. Gariano RF, Gardner TW: Retinal angiogenesis in development and disease. Nature 2005;438:960- 966.
36. Miller J W, Adamis A P, Aiello LP: Vascular endothe-lial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997;13:37-50.
37. Hernandez C, Fonollosa A, Garcia-Ramirez M, Higuera M, Catalan R, Miralles A, Garcia-Arumi J, Simo R: Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2006;29:2028-2033.
38. Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis-Evans J, Moriarty P, Khaliq A, Foreman D, Allamby D, Bardsley B: Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol 1997;81:228-233.
39. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM: A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. Metabolism 1989;38:586-589.
40. Krsek M, Skrha J, Sucharda P, Justova V, Lacinova Z: Changes in IGF-I levels and its binding proteins in diabetes mellitus and obesity. Cas Lek Cesk 2003; 142:216-219.
41. Meyer-Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Losche C, Rollmann R, Schatz H: Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest 1993;92:2620-2625.
42. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M: Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002;134:348-353.
43. Tang J, Zhu XW, Lust WD, Kern TS: Retina accumulates more glucose than does the embryologically similar cerebral cortex in diabetic rats. Diabetologia 2000;43:1417-1423.
44. Ola MS, Berkich DA, Xu Y, King MT, Gardner T W, Simpson I, Lanoue KF: Analysis of glucose metabolism in diabetic rat retinas. Am J Physiol Endocrinol Metab 2006;290:E1057-1067.
45. Xu Y, Ola MS, Berkich DA, Gardner T W, Barber AJ, Palmieri F, Hutson SM, Lanoue KF: Energy sources for glutamate neurotransmission in the retina: absence of the aspartate/glutamate carrier produces reliance on glycolysis in glia. J Neurochem 2007;101: 120-131.
46. The Diabetes Control and Complications Trial: The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 1995;113: 36-51.
47. Reiter CE, Gardner TW: Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy. Prog Retin Eye Res 2003;22:545-562.
48. Zhang L, Krzentowski G, Albert A, Lefebvre PJ: Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001;24:1275-1279.
49. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, Kohner EM: Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 2001;24: 284-289.
50. Stuhldreher WL, Becker DJ, Drash AL, Ellis D, Kuller LH, Wolfson SK, Orchard TJ: The association of waist/hip ratio with diabetes complications in an adult IDDM population. J Clin Epidemiol 1994; 47:447-456.
51. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, Turner RC: United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998;116:297-303.
52. Smith SB, Duplantier J, Dun Y, Mysona B, Roon P, Martin PM, Ganapathy V: In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine. Invest Ophthalmol Vis Sci 2008;49:4154-4161.
53. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA: Ciliary neu-rotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006;103:3896-3901.